Drugs / Tangningtongluo tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05007262 | Aug 2021 → Oct 2023 | diabetic retinopathy, type 2 diabetes mellitus | Guizhou Bailing Group Pharmaceutical Co Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tangningtongluo tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007262 ↗ |
| Route | Oral | “Tangningtongluo tablets(4 tablets,tid,po.)” NCT05007262 ↗ |